Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).

ABSTRACT:

Background

The therapeutic success of chemotherapeutic agents is often limited by severe adverse effects. To reduce toxicity of these drugs, nanoscale particle-based drug delivery systems (DDS) are used. DDS accumulate to some extent in tumor tissues, but only a very small portion of a given dose reaches this target. Accumulation of DDS in tumor tissues is supposed to be much faster than in certain other tissues in which side effects occur ("Kinetic Targeting"). Once saturation in tumor tissue is achieved, most of the administered DDS still circulate in the plasma. The extracorporeal elimination of these circulating nanoparticles would probably reduce toxicity.

Methods

For the CARL-trial (Controlled Application and Removal of Liposomal chemotherapeutics), pegylated liposomal

SUBMITTER: Eckes J 

PROVIDER: S-EPMC3175222 | biostudies-literature | 2011 Aug

REPOSITORIES: biostudies-literature